Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2015

01-06-2015 | Original Article

Upregulation of podocyte-secreted angiopoietin-like-4 in diabetic nephropathy

Authors: Jing Ma, Xiao Chen, Jian-Si Li, Lei Peng, Shi-Yao Wei, Shi-Lei Zhao, Tong Li, Dan Zhu, Yi-Xin He, Qiu-Ju Wei, Bing Li

Published in: Endocrine | Issue 2/2015

Login to get access

Abstract

Podocyte injury plays a key role in the development of diabetic nephropathy (DN). Understanding the changes in podocyte structure and function in diabetes mellitus may lead to novel diagnostic tools and treatment strategies for DN. Albuminuria, histological alterations, and podocyte injury were detected at different time points in streptozotocin (STZ)-induced diabetic rats. Increased urinary albumin-to-creatinine ratios (ACR) and podocyte injury were significantly observed 4 weeks post-STZ injection. We determined the glomerular expression and distribution of angiopoietin-like 4 (Angptl4) by immunofluorescence and real-time PCR. Glomerular Angptl4 expression was mostly colocalized with synaptopodin, a podocyte marker, with substantial additional overlap with the glomerular basement membrane (GBM). This finding indicated that Angptl4 might be primarily secreted by podocytes and moved toward the GBM. Moreover, we observed by Western blot analysis and ELISA that the urinary Angptl4 level was gradually upregulated in both STZ-induced rats and diabetic patients with microalbuminuria and macroalbuminuria. We further found that the increased glomerular Angptl4 expression was closely related to the urinary ACR level and podocyte injury. In addition, the urinary Angptl4 expression was closely associated with albuminuria in the rats and patients with DN. This study is the first to show that podocyte-secreted Angptl4 is upregulated in DN and can be detected in urine. Angptl4 might function as a podocyte injury marker and could be a potential and novel diagnostic and therapeutic biomarker for DN.
Appendix
Available only for authorised users
Literature
1.
R. Veelken, K.F. Hilgers, A. Hartner, A. Haas, K.P. Bohmer, R.B. Sterzel, Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy. J. Am. Soc. Nephrol. 11(1), 71–79 (2000)PubMed
2.
Y. Yamamoto, I. Kato, T. Doi, H. Yonekura, S. Ohashi, M. Takeuchi, T. Watanabe, S. Yamagishi, S. Sakurai, S. Takasawa, H. Okamoto, H. Yamamoto, Development and prevention of advanced diabetic nephropathy in rage-overexpressing mice. J. Clin. Investig. 108(2), 261–268 (2001)CrossRefPubMedCentralPubMed
3.
Standards of medical care in diabetes-2008, Diabetes care 31(Suppl 1), S12–54 (2008)
4.
A.I. Adler, R.J. Stevens, S.E. Manley, R.W. Bilous, C.A. Cull, R.R. Holman, Development and progression of nephropathy in type 2 diabetes: the united kingdom prospective diabetes study (ukpds 64). Kidney Int. 63(1), 225–232 (2003)CrossRefPubMed
5.
T. Ninomiya, V. Perkovic, B.E. de Galan, S. Zoungas, A. Pillai, M. Jardine, A. Patel, A. Cass, B. Neal, N. Poulter, C.E. Mogensen, M. Cooper, M. Marre, B. Williams, P. Hamet, G. Mancia, M. Woodward, S. Macmahon, J. Chalmers, Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J. Am. Soc. Nephrol. 20(8), 1813–1821 (2009)CrossRefPubMedCentralPubMed
6.
G. Gruden, P.C. Perin, G. Camussi, Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology. Curr. Diabetes Rev. 1(1), 27–40 (2005)CrossRefPubMed
7.
J.A. Jefferson, S.J. Shankland, R.H. Pichler, Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 74(1), 22–36 (2008)CrossRefPubMed
8.
F.S. Siddiqi, A. Advani, Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes. Diabetes 62(11), 3647–3655 (2013)CrossRefPubMedCentralPubMed
9.
D.P. Naidoo, The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes, Cardiovasc. J. S. Afr. 13(4), 194–199 (2002)
10.
H. Cheng, X. Fan, G.W. Moeckel, R.C. Harris, Podocyte cox-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression. J. Am. Soc. Nephrol. 22(7), 1240–1251 (2011)CrossRefPubMedCentralPubMed
11.
A.V. Cybulsky, T. Takano, J. Papillon, J. Guillemette, A.M. Herzenberg, C.R. Kennedy, Podocyte injury and albuminuria in mice with podocyte-specific overexpression of the ste20-like kinase, slk. Am. J. Pathol. 177(5), 2290–2299 (2010)CrossRefPubMedCentralPubMed
12.
H. Zhang, M. Schin, J. Saha, K. Burke, L.B. Holzman, W. Filipiak, T. Saunders, M. Xiang, C.W. Heilig, F.C. Brosius 3rd, Podocyte-specific overexpression of glut1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice. Am. J. Physiol. 299(1), F91–F98 (2010)
13.
Y. Oike, K. Yasunaga, T. Suda, Angiopoietin-related/angiopoietin-like proteins regulate angiogenesis. Int. J. Hematol. 80(1), 21–28 (2004)CrossRefPubMed
14.
Y. Kubota, Y. Oike, S. Satoh, Y. Tabata, Y. Niikura, T. Morisada, M. Akao, T. Urano, Y. Ito, T. Miyamoto, N. Nagai, G.Y. Koh, S. Watanabe, T. Suda, Cooperative interaction of angiopoietin-like proteins 1 and 2 in zebrafish vascular development. Proc. Natl. Acad. Sci. USA 102(38), 13502–13507 (2005)CrossRefPubMedCentralPubMed
15.
A. Galaup, A. Cazes, S. Le Jan, J. Philippe, E. Connault, E. Le Coz, H. Mekid, L.M. Mir, P. Opolon, P. Corvol, C. Monnot, S. Germain, Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness. Proc. Natl. Acad. Sci. USA 103(49), 18721–18726 (2006)CrossRefPubMedCentralPubMed
16.
S. Kersten, S. Mandard, N.S. Tan, P. Escher, D. Metzger, P. Chambon, F.J. Gonzalez, B. Desvergne, W. Wahli, Characterization of the fasting-induced adipose factor fiaf, a novel peroxisome proliferator-activated receptor target gene. J. Biol. Chem. 275(37), 28488–28493 (2000)CrossRefPubMed
17.
S. Mandard, F. Zandbergen, E. van Straten, W. Wahli, F. Kuipers, M. Muller, S. Kersten, The fasting-induced adipose factor/angiopoietin-like protein 4 is physically associated with lipoproteins and governs plasma lipid levels and adiposity. J. Biol. Chem. 281(2), 934–944 (2006)CrossRefPubMed
18.
J.C. Yoon, T.W. Chickering, E.D. Rosen, B. Dussault, Y. Qin, A. Soukas, J.M. Friedman, W.E. Holmes, B.M. Spiegelman, Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol. Cell. Biol. 20(14), 5343–5349 (2000)CrossRefPubMedCentralPubMed
19.
L.C. Clement, C. Avila-Casado, C. Mace, E. Soria, W.W. Bakker, S. Kersten, S.S. Chugh, Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat. Med. 17(1), 117–122 (2011)CrossRefPubMedCentralPubMed
20.
B. Li, A. Cohen, T.E. Hudson, D. Motlagh, D.L. Amrani, J.S. Duffield, Mobilized human hematopoietic stem/progenitor cells promote kidney repair after ischemia/reperfusion injury. Circulation 121(20), 2211–2220 (2010)CrossRefPubMedCentralPubMed
21.
S.L. Lin, B. Li, S. Rao, E.J. Yeo, T.E. Hudson, B.T. Nowlin, H. Pei, L. Chen, J.J. Zheng, T.J. Carroll, J.W. Pollard, A.P. McMahon, R.A. Lang, J.S. Duffield, Macrophage wnt7b is critical for kidney repair and regeneration. Proc. Natl. Acad. Sci. USA 107(9), 4194–4199 (2010)CrossRefPubMedCentralPubMed
22.
L. Peng, J. Ma, R. Cui, X. Chen, S.Y. Wei, Q.J. Wei, B. Li, The calcineurin inhibitor tacrolimus reduces proteinuria in membranous nephropathy accompanied by a decrease in angiopoietin-Like-4. Plos One 9(8), e106164 (2014)
23.
T.D. Schmittgen, K.J. Livak, Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3(6), 1101–1108 (2008)CrossRefPubMed
24.
E. Mandache, M. Penescu, Nanostructural features of diabetic podocytopathy. Rom. J. Morphol. Embryol. 53(1), 23–27 (2012)PubMed
25.
J.J. Li, S.J. Kwak, D.S. Jung, J.J. Kim, T.H. Yoo, D.R. Ryu, S H. Han, H.Y. Choi, J.E. Lee, S.J. Moon, D.K. Kim, D.S. Han, S.W. Kang, Podocyte biology in diabetic nephropathy, Kidney Int. (Supplement no. 106), S36–42 (2007)
26.
G. Wolf, F.N. Ziyadeh, Cellular and molecular mechanisms of proteinuria in diabetic nephropathy. Nephron. Physiol. 106(2), 26–31 (2007)CrossRef
27.
R.N. Moresco, M.B. Sangoi, J.A. De Carvalho, E. Tatsch, G.V. Bochi, Diabetic nephropathy: traditional to proteomic markers. Clin. Chim. Acta 421, 17–30 (2013)CrossRefPubMed
28.
S.J. Shankland, The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 69(12), 2131–2147 (2006)CrossRefPubMed
29.
G. Wolf, S. Chen, F.N. Ziyadeh, From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 54(6), 1626–1634 (2005)CrossRefPubMed
30.
A. Georgiadi, L. Lichtenstein, T. Degenhardt, M.V. Boekschoten, M. van Bilsen, B. Desvergne, M. Muller, S. Kersten, Induction of cardiac angptl4 by dietary fatty acids is mediated by peroxisome proliferator-activated receptor beta/delta and protects against fatty acid-induced oxidative stress. Circ. Res. 106(11), 1712–1721 (2010)CrossRefPubMed
31.
A.M. Ordelheide, M. Heni, C. Thamer, F. Machicao, A. Fritsche, N. Stefan, H.U. Haring, H. Staiger, In vitro responsiveness of human muscle cell peroxisome proliferator-activated receptor delta reflects donors’ insulin sensitivity in vivo. Eur. J. Clin. Invest. 41(12), 1323–1329 (2011)CrossRefPubMed
32.
M.R. Robciuc, P. Skrobuk, A. Anisimov, V.M. Olkkonen, K. Alitalo, R.H. Eckel, H.A. Koistinen, M. Jauhiainen, C. Ehnholm, Angiopoietin-like 4 mediates ppar delta effect on lipoprotein lipase-dependent fatty acid uptake but not on beta-oxidation in myotubes, PloS one 7(10), e46212 (2012)
33.
K. Yoshida, T. Shimizugawa, M. Ono, H. Furukawa, Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase, J. Lipid Res. 43(11), 1770–1772 (2002)
34.
D. Padua, X.H. Zhang, Q. Wang, C. Nadal, W.L. Gerald, R.R. Gomis, J. Massague, Tgfbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133(1), 66–77 (2008)CrossRefPubMedCentralPubMed
35.
S.H. Kim, Y.Y. Park, S.W. Kim, J.S. Lee, D. Wang, R.N. DuBois, Angptl4 induction by prostaglandin e2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res. 71(22), 7010–7020 (2011)CrossRefPubMedCentralPubMed
36.
Y.Y. Goh, M. Pal, H.C. Chong, P. Zhu, M.J. Tan, L. Punugu, C.K. Tan, R.L. Huang, S.K. Sze, M.B. Tang, J.L. Ding, S. Kersten, N.S. Tan, Angiopoietin-like 4 interacts with matrix proteins to modulate wound healing. J. Biol. Chem. 285(43), 32999–33009 (2010)CrossRefPubMedCentralPubMed
37.
P. Zhu, M.J. Tan, R.L. Huang, C.K. Tan, H.C. Chong, M. Pal, C.R. Lam, P. Boukamp, J.Y. Pan, S.H. Tan, S. Kersten, H.Y. Li, J.L. Ding, N.S. Tan, Angiopoietin-like 4 protein elevates the prosurvival intracellular O2(−):H2O2 ratio and confers anoikis resistance to tumors. Cancer Cell 19(3), 401–415 (2011)CrossRefPubMed
38.
M.C. Smart-Halajko, M.R. Robciuc, J.A. Cooper, M. Jauhiainen, M. Kumari, M. Kivimaki, K.T. Khaw, S.M. Boekholdt, N.J. Wareham, T.R. Gaunt, I.N. Day, P.S. Braund, C.P. Nelson, A.S. Hall, N.J. Samani, S.E. Humphries, C. Ehnholm, P.J. Talmud, The relationship between plasma angiopoietin-like protein 4 levels, angiopoietin-like protein 4 genotype, and coronary heart disease risk. Arterioscler. Thromb. Vasc. Biol. 30(11), 2277–2282 (2010)CrossRefPubMedCentralPubMed
39.
A. Galaup, E. Gomez, R. Souktani, M. Durand, A. Cazes, C. Monnot, J. Teillon, S. Le Jan, C. Bouleti, G. Briois, J. Philippe, S. Pons, V. Martin, R. Assaly, P. Bonnin, P. Ratajczak, A. Janin, G. Thurston, D.M. Valenzuela, A.J. Murphy, G.D. Yancopoulos, R. Tissier, A. Berdeaux, B. Ghaleh, S. Germain, Protection against myocardial infarction and no-reflow through preservation of vascular integrity by angiopoietin-like 4. Circulation 125(1), 140–149 (2012)CrossRefPubMed
Metadata
Title
Upregulation of podocyte-secreted angiopoietin-like-4 in diabetic nephropathy
Authors
Jing Ma
Xiao Chen
Jian-Si Li
Lei Peng
Shi-Yao Wei
Shi-Lei Zhao
Tong Li
Dan Zhu
Yi-Xin He
Qiu-Ju Wei
Bing Li
Publication date
01-06-2015
Publisher
Springer US
Published in
Endocrine / Issue 2/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0486-5

Other articles of this Issue 2/2015

Endocrine 2/2015 Go to the issue

Research Letter

Renal tubular markers in pregnant women with and without gestational diabetes mellitus: a pilot study

Original Article

Effect of perceived racial discrimination on self-care behaviors, glycemic control, and quality of life in adults with type 2 diabetes

Editorial

Autoantibodies of β-adrenergic and M2 cholinergic receptors: atrial fibrillation in hyperthyroidism

Original Article

Frequency of nodular goiter and autoimmune thyroid disease in patients with polycystic ovary syndrome

Review

Epigenetic alterations in human parathyroid tumors

Original Article

Time course of IL-15 expression after acute resistance exercise in trained rats: effect of diabetes and skeletal muscle phenotype
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits